Article · Wikipedia archive · Last revised Jul 24, 2026

Lys-MDA

Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland. A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024. The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.

Last revised
Jul 24, 2026
Read time
≈ 1 min
Length
303 w
Citations
9
Source
Wikipedia ↗
Lys-MDA
Clinical data
Other namesN-(L-Lysinamidyl)-MDA; N-(L-Lysinamidyl)-3,4-methylenedioxyamphetamine
Routes of
administration		Oral1
Drug classSerotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT2 receptor agonist; Entactogen; Empathogen; Serotonergic psychedelic; Hallucinogen; Stimulant
ATC code
  • None
Pharmacokinetic data
MetabolitesMDA1
Identifiers
  • (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number
ChemSpider
Chemical and physical data
FormulaC16H25N3O3
Molar mass307.394 g·mol−1
3D model (JSmol)
  • CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN
  • InChI=1S/C16H25N3O3/c1-11(19-16(20)13(18)4-2-3-7-17)8-12-5-6-14-15(9-12)22-10-21-14/h5-6,9,11,13H,2-4,7-8,10,17-18H2,1H3,(H,19,20)/t11?,13-/m0/s1
  • Key:ZUWUZALZPUJLCD-YUZLPWPTSA-N

Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action.1 Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.2345 A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.6 The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.1

Interactions

See also

See also

References

References

  1. Straumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, Eckert A, Luethi D, Rudin D, Liechti ME (September 2025). "Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants". Neuropsychopharmacology. 51 (2): 476–485. doi:10.1038/s41386-025-02248-3. PMC 12708835. PMID 40999236.
  2. Buntz B (21 September 2022). "MindMed announces Phase 1 study of MDMA-like substances". Drug Discovery and Development.
  3. "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". Biospace.com. 20 September 2022.
  4. WO 2022/053696, Grill M, "Novel Safrylamine derivatives having prodrug properties.", published 17 March 2022, assigned to Compass Pathfinder Limited. 
  5. WO 2023/283373, Clark S, Duncton MA, "Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof", published 12 January 2023, assigned to Terran Biosciences Inc. 
  6. "ClinicalTrials.gov". ClinicalTrials.gov. 13 August 2024. Retrieved 13 November 2024.
External links